Bio-Rad Laboratories' (NYSE:BIO) stock performance has been a mixed bag in recent periods. The mixed performance can be attributed to
softness in the BioPharma segment,
stiff competition and various institution's recent
stock position reductions. Despite this, they have successful
earnings reports which frequently beat estimates, albeit while missing on revenue in Q1 2024. Innovation has been strong within the company referring to a
healthy balance sheet and consistent growth albeit facing headwinds. The company projected a positive outlook for 2024, yet saw share slip due to a recent reiteration of their
revenue growth outlook. Expansion of portfolio can be seen with their pursuit to merge with
Qiagen. Noteworthy movement includes Bio Rad's stock rallying 90% after announcing a partnership with
Oncocyte and the appointment of a new
EVP and CFO. This includes an investment by
Roubaix Capital LLC of $4.05 million but met with selling by various institutions and investors.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Sat, 18 May 2024 21:49:27 GMT -
Rating 0
- Innovation 4
- Information 5
- Rumor -2
